Kras and Tumor Immunity: Friend or Foe?

Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a031849. doi: 10.1101/cshperspect.a031849.

Abstract

With the recent breakthroughs in immunotherapy as curative treatments in certain tumor types, there has been renewed interest in the relationship between immunity and tumor growth. Although we are gaining a greater understanding of the complex interplay of immune modulating components in the tumor microenvironment, the specific role that tumor cells play in shaping the immune milieu is still not well characterized. In this review, we focus on how mutant Kras tumor cells contribute to tumor immunity, with a specific focus on processes induced directly or indirectly by the oncogene.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Gene Regulatory Networks*
  • Humans
  • Immunotherapy
  • Mutation
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Neoplasms / therapy
  • Proto-Oncogene Proteins p21(ras) / genetics*
  • Tumor Microenvironment

Substances

  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)